Endo looks for more acquisitions

Endo Pharmaceuticals' CEO David Holveck, a Johnson & Johnson alum, is modeling his company after the Big Pharma. Gabelli & Co analyst Kevin Kedra notes that Lidoderm--a patch to treat post-shingles nerve pain--will account for 47 percent of Endo's 2010 sales. Faced with the the loss of patent protection for it's main drug in 2015, the pharma company has been making deals to diversify. Since Holveck took over at Endo in 2008, he's had in excess of $1...

Endo buying partner in pain Penwest for $168M

Looking to burnish its reputation in the field of pain therapy, Chadds Ford, PA-based Endo Pharmaceuticals (ENDP) struck a deal to buy out its development partner Penwest Pharmaceuticals for about $168 million on the same day it filed an NDA for a new, abuse-resistant drug. The buyout deal--struck at a price of $5 per share, a 19 percent premium--gives the developer Penwest's interests in Opana ER, a therapy that the two biotech companies have been working on for the past 13 years, along with a...

Endo Pharma to buy HealthTronics in $223M deal

Endo Pharmaceuticals is planning to buy HealthTronics for $223 million, offering a 34 percent premium for shares that closed at $3.62. If the deal goes through as planned, HealthTronics, which markets urology products and services, will be made a wholly owned subsidiary of Endo, which has been diversifying recently to broaden its revenue sources. "Beyond diversifying our revenue base, the acquisition of HealthTronics further positions Endo as a preferred healthcare provider of multiple medical...